Eligibility criteria
Studies where >20% of participants were pediatric
(< 18 years of age) and diagnosed with “refractory” or
“treatment-resistant” ITP were included in this systematic review. For
inclusion, studies needed to report on diagnostic criteria, laboratory
work-up, or treatments other than first- line therapy (short course
prednisone, IVIG, or anti-D). Commentaries, editorials, narrative
reviews, conference abstracts, reviews, case reports or case series with
fewer than ten patients were excluded.